Combination therapy with interferon-beta and glatiramer acetate in multiple sclerosis

Acta Neurologica Scandinavica

Volumn 116, Issue 2, 2007, Pages 96-99

  Ytterberg, C ^a   Johansson, S ^a   Andersson, M ^a   Olsson, D ^b   Link, H ^b   Holmqvist, L W ^a   Von Koch, L ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Combination therapy; Glatiramer acetate; Interferon beta; Multiple sclerosis; Multiple Sclerosis Functional Composite; Observational study

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE;

ADULT; ARTICLE; ASTHENIA; CHILL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DYSPNEA; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HAIR LOSS; HEART PALPITATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LONGITUDINAL STUDY; MALAISE; MALE; MONOTHERAPY; MULTIPLE SCLEROSIS; MYALGIA; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PSYCHOLOGICAL ASPECT; RELAPSE; SIDE EFFECT; SLEEP DISORDER; STATISTICAL MODEL; SWEATING; SWELLING; TISSUE REACTION; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; XEROSTOMIA;

ADULT; BIOLOGICAL RESPONSE MODIFIERS; COGNITION DISORDERS; DEPRESSION; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PEPTIDES; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 34547418139     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2007.00801.x     Document Type: Article

References (11)

1. Goodin DS, Frohman EM, Garmany GP Jr. et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002 58 : 169 78.
2. Munari LM, Filippini G. Lack of evidence for use of glatiramer acetate in multiple sclerosis. Lancet Neurol 2004 3 : 641.
3. Benson K, Hartz A. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000 342 : 1878 86.
4. Lublin F, Cutter G, Elfont R, Khan O, Lisak R, Mc Farland H. A trial to assess the safety of combining therapy with interferon beta-1a and glatiramer acetate in patients with relapsing MS. Neurology 2001 56 (Suppl. 3 A148 A.
5. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983 77 : 1444 52.
6. Lublin F, Baier M, Cutter G et al. Results of the extension of a trial to assess the longer term safety of combining interferon beta-1a and glatiramer acetate. Neurology 2002 58 (Suppl. 3 A85 A.
7. Cutter GR, Baier ML, Rudick RA et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999 122 : 871 82.
8. Uitdehaag BMJ, Ader HJ, Roosma TJA, de Groot V, Kalkers NF, Polman CH. Multiple sclerosis functional composite: impact of reference population and interpretation of changes. Mult Scler 2002 8 : 366 71.
9. Smith A. Symbol Digit Modalities Test (SDMT). In : Lezak M, ed. Neuropsychological assessment, 3rd edn. New York : Oxford University Press, 1982 379 81.
10. Beck AT, Steer RA, Garbin MG. Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation. Clin Psychol Rev 1988 8 : 77 100.
11. Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain 2001 124 : 962 73.